Loading...

BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC Management Changes 8-K Filing

BRDG

BBT

BRIDGEBIO ONCOLOGY THERAPEUTICS INC

(BBOT)

2026 8-K

Management Change

Leadership Changes

Financial Results Report

New Clinical Data

Quarterly Results Report

Business Combination

Asset Acquisitions

Business Combination

Business Combination

Business Combination

Director Appointment

External Links:

On April 20, 2026, Dr. Eli Wallace resigned as a director and CEO of BridgeBio Oncology, succeeded by Dr. Pedro Beltran; Dr. Wallace will provide advisory services and retain stock options for continued vesting.

AI Assistant

BRIDGEBIO ONCOLOGY THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.